(Total Views: 672)
Posted On: 02/14/2022 11:38:33 AM
Post# of 148899
Good day to all longs.
Some "dispersed" thoughts ....
The communication style of the new board can and might be different. They are required to communicate with us only as required by SEC regulations.
As much as I miss the (price dropping) frequent Proactive updates and beautiful Christine, a change of management means that, probably, we will not get updates as often as we were, and in the same "tone" as before (if you get my point) .
This does not mean that LL is not binding to the CCR5 receptor
as ToTheMoonAlice rightly points out.
NASH, Cancer and LH patients are being treated as we speak. Data is being gathered. The BLA for HIV is being prepared.
What I am trying to point out is hat time is working in our advantage as far as data gathering goes (yes, and not so as far as financing goes).
At this point we need to trust the BOD to do the right thing (find a good CEO) and due diligence with data gathering and application(s) to FDA.
The talk of partnership and/or BO is just this: talk. We do no have any solid information telling us one way or another if these rumors are true or not. They are just rumors and, as far as I am concerned, to a large extent, wishful thinking (unless demonstrated otherwise). Don't get me wrong, if somebody tells me that partnership with a good pharmaceutical company is in the works to advance, say, a large NASH clinical trial with good financing for CYDY, I would like to hear about it.
But, again, the fundamental value of the company has not changed: we have a great drug.
The question is if the "new" management (sans Nader) can bring the ship to port, get an approval and then the dam will be broken.
We will find out soon as there are many rabbits in the hat. The silence will be broken when something happens (or at maximum 4 days afterwards ), I think this will be soon.
In the mean time I will keep on dreaming of Christine ....
Some "dispersed" thoughts ....
The communication style of the new board can and might be different. They are required to communicate with us only as required by SEC regulations.
As much as I miss the (price dropping) frequent Proactive updates and beautiful Christine, a change of management means that, probably, we will not get updates as often as we were, and in the same "tone" as before (if you get my point) .
This does not mean that LL is not binding to the CCR5 receptor
as ToTheMoonAlice rightly points out. NASH, Cancer and LH patients are being treated as we speak. Data is being gathered. The BLA for HIV is being prepared.
What I am trying to point out is hat time is working in our advantage as far as data gathering goes (yes, and not so as far as financing goes).
At this point we need to trust the BOD to do the right thing (find a good CEO) and due diligence with data gathering and application(s) to FDA.
The talk of partnership and/or BO is just this: talk. We do no have any solid information telling us one way or another if these rumors are true or not. They are just rumors and, as far as I am concerned, to a large extent, wishful thinking (unless demonstrated otherwise). Don't get me wrong, if somebody tells me that partnership with a good pharmaceutical company is in the works to advance, say, a large NASH clinical trial with good financing for CYDY, I would like to hear about it.
But, again, the fundamental value of the company has not changed: we have a great drug.
The question is if the "new" management (sans Nader) can bring the ship to port, get an approval and then the dam will be broken.
We will find out soon as there are many rabbits in the hat. The silence will be broken when something happens (or at maximum 4 days afterwards
), I think this will be soon. In the mean time I will keep on dreaming of Christine ....
(11)
(0)Scroll down for more posts ▼
